Share ownership H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 15/06/2026 pm IST			5-day change	1st Jan Change
43.24 ^DKK	-1.05%		+0.05%	+0.19%

15/06	H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease	CI
05/06	H. Lundbeck A/S - Special Call

Share class: H. Lundbeck A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	79,65,92,888	26,66,63,886 ( 33.48 %)	34,64,464 ( 0.4349 %)	30.76 %
Stock B	10	19,91,48,222	3,95,79,850 ( 19.87 %)	1,27,465 ( 0.064 %)

Major shareholders: H. Lundbeck A/S

Name	Stocks	%	Valuation
Lundbeckfonden 66 %	52,57,51,306	66 %	3 564 M kr
Sector Gamma AS 0.2367 %	18,85,688	0.2367 %	13 M kr
BNP Paribas Asset Management Belgium SA 0.1588 %	12,64,786	0.1588 %	9 M kr
Mackenzie Investments Corp. (United States) 0.1533 %	12,21,437	0.1533 %	8 M kr
Canaccord Genuity Wealth Ltd. 0.1226 %	9,76,610	0.1226 %	7 M kr
Nykredit Bank A/S (Investment Management) 0.1158 %	9,22,182	0.1158 %	6 M kr
Schroder Investment Management (Europe) SA (Finland) 0.0665 %	5,30,000	0.0665 %	4 M kr
Anima Sgr SpA 0.0483 %	3,85,117	0.0483 %	3 M kr
AllianceBernstein Ltd. 0.0472 %	3,76,254	0.0472 %	3 M kr
Lars Bang 0.0452 %	3,60,328	0.0452 %	2 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Lundbeckfonden 80 %	15,93,18,578	80 %	915 M kr
Nykredit Bank A/S (Investment Management) 0.4193 %	8,34,974	0.4193 %	5 M kr
Sparinvest SA (Denmark) 0.1092 %	2,17,489	0.1092 %	1 M kr
Equinor Asset Management ASA 0.0527 %	1,05,000	0.0527 %	603 345 kr
Niche Asset Management Ltd. 0.0461 %	91,744	0.0461 %	527 174 kr
Lars Bang 0.0452 %	90,082	0.0452 %	517 624 kr
Dorothea Wenzel 0.0226 %	45,000	0.0226 %	258 576 kr
AL Sydbank A/S (Investment Management) 0.0166 %	33,027	0.0166 %	189 778 kr
Johan Luthman 0.0131 %	26,049	0.0131 %	149 681 kr
Research Affiliates LLC 0.0032 %	6,373	0.0032 %	36 620 kr
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Others	86%
Institutional	1.67%
Individuals	0.11%
Unknown	12.22%

Based on 1000 largest holdings

Geographical origin of shareholders

Denmark	86.26%
Norway	0.29%
United Kingdom	0.28%
United States	0.17%
Belgium	0.16%
Individuals	0.11%
Finland	0.08%
Italy	0.06%
Switzerland	0.06%
Germany	0.05%
France	0.05%
Sweden	0.05%
Cyprus	0.04%
Liechtenstein	0.04%
Austria	0.02%
Canada	0.02%
Luxembourg	0.01%
Spain	0.01%
Estonia	0.01%
Ireland	0.01%

Based on 1000 largest holdings

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâ€™s disease, Bipolar disorder, depression, epilepsy, Huntingtonâ€™s disease, Parkinsonâ€™s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâ€™s disease, Azilect for the treatment of Parkinsonâ€™s disease, Xenazine for the treatment of Huntingtonâ€™s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Employees

5,000

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company